Ether

Ether

SCHEMBL343655

CCOCC.Oc1ccc(O)c(Cc2ccccc2)c1

nearest known ligand 0.57

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 1/20 0.57
MEN1 O00255 2/20 0.54
KMT2A Q03164 2/20 0.54
CYP3A4 P08684 1/20 0.54
HPGD P15428 1/20 0.54
ALOX15 P16050 1/20 0.54
HIF1A Q16665 1/20 0.54
HSD17B10 Q99714 1/20 0.54
BCL2 P10415 1/20 0.50
BCL2L1 Q07817 1/20 0.50
KEAP1 Q14145 1/20 0.47
SLC7A5 Q01650 1/20 0.44
IDH1 O75874 1/20 0.43
HSP90AA1 P07900 3/20 0.43
LMNA P02545 2/20 0.41
GAA P10253 2/20 0.41
MAPT P10636 2/20 0.41
HTT P42858 2/20 0.41
HSD17B3 P37058 1/20 0.41
PKM P14618 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Butane SCHEMBL27663673 0.88 ALOX5 (0.62) ALOX5MEN1KMT2ACYP3A4HPGD
SCHEMBL390179 0.88 ALOX5 (0.71) ALOX5MEN1KMT2ACYP3A4HPGD
Ether SCHEMBL19915209 0.83 KEAP1 (0.58) ALOX5MEN1KMT2ACYP3A4HPGD
SCHEMBL8430733 0.78 KEAP1 (0.59) ALOX5MEN1KMT2ACYP3A4HPGD
Ether SCHEMBL19915274 0.78 DRD2 (0.47) ALOX5IDH1
Ether SCHEMBL8754573 0.77 BCL2 (0.46) ALOX5MEN1KMT2ACYP3A4HPGD
SCHEMBL4517872 0.76 MEN1 (0.61) ALOX5MEN1KMT2ACYP3A4HPGD
SCHEMBL10906425 0.75 PTPN1 (0.47) ALOX5BCL2BCL2L1
SCHEMBL11764362 0.75 ALOX5 (0.74) ALOX5MEN1KMT2ACYP3A4HPGD
Diphenylmethane SCHEMBL4694519 0.74 CALM1 (0.63) CYP3A4IDH1LMNAMAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120014888-A1 Matte Skin Finish Compositions AMCOL INTERNATIONAL CORPORATION (US) 2012-01-19 US disclosed
US-20100330007-A1 Imrpoved Skin Brightening Compositions AMCOL INTERNATIONAL CORPORATION (US) 2010-12-30 US disclosed
EP-2247279-A1 IMPROVED SKIN BRIGHTENING COMPOSITIONS AMCOL INTERNATIONAL CORPORATION (US) 2010-11-10 EP disclosed
WO-2010088185-A2 MATTE SKIN FINISH COMPOSITIONS AMCOL INTERNATIONAL CORPORATION (US) 2010-08-05 WO disclosed
WO-2009099911-A1 IMPROVED SKIN BRIGHTENING COMPOSITIONS AMCOL INTERNATIONAL CORPORATION (US) 2009-08-13 WO disclosed
US-20080214669-A1 Composition and Method For Treating Hyperpigmented Skin LIPO CHEMICALS INC. (US) 2008-09-04 US disclosed
EP-1835884-A2 COMPOSITION AND METHOD FOR TREATING HYPERPIGMENTED SKIN LIPO CHEMICALS INC (US) 2007-09-26 EP disclosed
US-20070166251-A1 Composition and method for treating hyperpigmented skin LIPO CHEMICALS INC. (US) 2007-07-19 US disclosed
WO-2006078399-A2 COMPOSITION AND METHOD FOR TREATING HYPERPIGMENTED SKIN LIPO CHEMICALS, INC. (US) 2006-07-27 WO disclosed
WO-2001017497-A1 DEPIGMENTING COMPOSITIONS GHISALBERTI CARLO (BR) 2001-03-15 WO disclosed
US-5607692-A MIXTURE OF TWO LIPID VESICLE DISPERSIONS: FIRST FOR DEEP LAYER TREATMENT HAS ANTI- OR DE-PIGMENTING AGENT OR TYROSINASE INHIBITOR; SECOND FOR SURFACE LAYER TREATMENT HAS KERATOLYTIC, MOISTURIZING OR PROTECTIVE AGENT L'OREAL (FR) 1997-03-04 US disclosed
EP-0341664-B1 SKIN DEPIGMENTAL AGENT KURARAY CO., LTD. (JP) 1992-08-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080214669-A1 Composition and Method For Treating Hyperpigmented Skin MC1R, MMS19, CUTA ALOX5 660/4885MEN1 74/4885KMT2A 2569/4885
US-20070166251-A1 Composition and method for treating hyperpigmented skin MMS19, CUTA, FAM20C ALOX5 1433/4885MEN1 376/4885KMT2A 2691/4885
US-20100330007-A1 Imrpoved Skin Brightening Compositions RARG, RBP4, RARA ALOX5 2205/4885MEN1 2714/4885KMT2A 1365/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.